Clinical trial
Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in…
NCT00379015 · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan, Other · Completed
Key facts
| NCT number | NCT00379015 |
|---|---|
| Title | Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer |
| Official title | Neoadjuvant Epirubicin/Cyclophosphamide Followed by Docetaxel Combined With Trastuzumab for the Patients With HER-Positive Advanced Breast Cancer |
| Lead sponsor | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | trastuzumab, cyclophosphamide, docetaxel, epirubicin hydrochloride, conventional surgery, neoadjuvant therapy |
| Enrollment | 38 |
| Start date | Jan 1, 2006 |
| Primary completion | Mar 1, 2016 |
| Completion | Mar 1, 2016 |
| First posted | Sep 21, 2006 |
| Last update posted | Sep 28, 2016 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: